Back    Zoom +    Zoom -
CANBRIDGE-B Leaps 5%+ After Announcing 14.7% Discounted Shr Placement to WUXI BIO's Subsidiary
Recommend
1
Positive
0
Negative
2
CANBRIDGE-B (01228.HK) announced the placement of 84.0336 million shares (around 14.12% of the enlarged share capital) to WuXi Biologics HealthCare Venture, a subsidiary of WUXI BIO (02269.HK), at a price of HKD2.38 per share, a 14.7% discount to the closing price of HKD2.79 on February 13.

The total fundraising from this placement will amount to HKD200 million, with net proceeds of around HKD199 million.

Related NewsDaiwa: WUXI BIO (02269.HK) Sees Significant Gross Margin Improvement; 2H25 NP Forecast Beats
CANBRIDGE-B opened 3.23% higher today and once peaked at HKD2.93. It last traded at HKD2.93, up 5.02%, with a volume of 20,000 shares, involving HKD57,700.
AAStocks Financial News